Abstract

BACKGROUND: Monitoring changes in pharyngeal carriage of pneumococcus in children following 13-valent pneumococcal conjugate vaccine (PCV13) introduction in the UK in 2010 informs understanding of patterns of invasive pneumococcal disease (IPD) incidence. METHODS: Nasopharyngeal swabs from healthy children vaccinated with PCV13 according to schedule (2, 4, 12 months) were cultured and serotyped. Results for children aged 13-48 months were compared between 2014/15 and 2017/19, and with children aged 6-12 months (2017/20). Blood was obtained from a subset of children for pneumococcal serotype-specific IgG. RESULTS: Total pneumococcal carriage at 13-48 months was 47.9% (473/988) in 2014/15 and 51.8% (412/795) in 2017/19 (p = 0.10); at age 6-12 months this value was 44.6% (274/615). In 2017/19, 2.9% (95% CI 1.8-4.3%) of children aged 13-48 months carried PCV13 serotypes (mainly 3 (1.5%) and 19A (0.8%)) and over 20% carried the additional PCV20 serotypes. Similar proportions of children had IgG ≥0.35 IU/mL for each serotype in 2014/15 and 2017/19.Serotype 7C carriage increased significantly (p < 0.01) between 2014/15 and 2017/19. Carriage of PCV20 serotypes 8 and 12F, both major causes of IPD, was rare. DISCUSSION: Introduction of PCV20, if licensed for children, could significantly change the composition of pneumococcal serotypes carried in the pharynx of UK children.